SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

Search

Fresenius SE & Co KGaA

Gesloten

SectorGezondheidszorg

43.68 -0.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.67

Max

43.93

Belangrijke statistieken

By Trading Economics

Inkomsten

-2M

343M

Verkoop

-96M

5.5B

K/W

Sectorgemiddelde

21.463

57.05

Dividendrendement

2.29

Winstmarge

6.253

Werknemers

176,486

EBITDA

-87M

741M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.01% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.29%

2.52%

Volgende Winsten

6 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.3B

25B

Vorige openingsprijs

44.16

Vorige sluitingsprijs

43.68

Nieuwssentiment

By Acuity

45%

55%

146 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Fresenius SE & Co KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2025, 10:45 UTC

Marktinformatie
Winsten

Fresenius Beats Subdued Expectations -- Market Talk

7 mei 2025, 06:55 UTC

Marktinformatie
Winsten

Fresenius's Outlook Is Achievable -- Market Talk

Peer Vergelijking

Prijswijziging

Fresenius SE & Co KGaA Prognose

Koersdoel

By TipRanks

28.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.4 EUR  28.01%

Hoogste 58 EUR

Laagste 50 EUR

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fresenius SE & Co KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Technische score

By Trading Central

42.5 / 43.2Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

146 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
help-icon Live chat